{"title":"肿瘤细胞组pd-l1特征表达用于抗癌药物和免疫检查点抑制剂相互作用的临床前研究","authors":"T.A. Bogush, A.A. Basharin, A.M. Scherbakov, K.I. Chandran, A.L. Mikhailova, I.P. Romanov, E.A. Bogush, V.S. Kosorukov","doi":"10.55959/msu0579-9384-2-2023-64-1-26-34","DOIUrl":null,"url":null,"abstract":"PD-L1 (Programmed death-ligand 1), a membrane protein of the immunoglobulin superfamily, is one of the targets for cancer immunotherapy. A panel of 14 cancer cell cultures with different constitutive PD-L1 expression level was formed and characterized. The panel is recommended for preclinical studies of a cytostatic drug effect on PD-L1 expression and for predicting the ef cacy of their combination with immune checkpoint inhibitors.","PeriodicalId":23660,"journal":{"name":"Vestnik Moskovskogo Universiteta Seriya 2 Khimiya","volume":"16 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"TUMOR CELL PANEL WITH CHARACTERIZED EXPRESSION OF PD-L1 FOR PRECLINICAL STUDIES OF ANTICANCER DRUGS AND IMMUNE CHECKPOINT INHIBITORS INTERACTION\",\"authors\":\"T.A. Bogush, A.A. Basharin, A.M. Scherbakov, K.I. Chandran, A.L. Mikhailova, I.P. Romanov, E.A. Bogush, V.S. Kosorukov\",\"doi\":\"10.55959/msu0579-9384-2-2023-64-1-26-34\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"PD-L1 (Programmed death-ligand 1), a membrane protein of the immunoglobulin superfamily, is one of the targets for cancer immunotherapy. A panel of 14 cancer cell cultures with different constitutive PD-L1 expression level was formed and characterized. The panel is recommended for preclinical studies of a cytostatic drug effect on PD-L1 expression and for predicting the ef cacy of their combination with immune checkpoint inhibitors.\",\"PeriodicalId\":23660,\"journal\":{\"name\":\"Vestnik Moskovskogo Universiteta Seriya 2 Khimiya\",\"volume\":\"16 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Vestnik Moskovskogo Universiteta Seriya 2 Khimiya\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.55959/msu0579-9384-2-2023-64-1-26-34\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vestnik Moskovskogo Universiteta Seriya 2 Khimiya","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.55959/msu0579-9384-2-2023-64-1-26-34","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
TUMOR CELL PANEL WITH CHARACTERIZED EXPRESSION OF PD-L1 FOR PRECLINICAL STUDIES OF ANTICANCER DRUGS AND IMMUNE CHECKPOINT INHIBITORS INTERACTION
PD-L1 (Programmed death-ligand 1), a membrane protein of the immunoglobulin superfamily, is one of the targets for cancer immunotherapy. A panel of 14 cancer cell cultures with different constitutive PD-L1 expression level was formed and characterized. The panel is recommended for preclinical studies of a cytostatic drug effect on PD-L1 expression and for predicting the ef cacy of their combination with immune checkpoint inhibitors.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
